First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study-Reference-Cited by-同舟云学术

First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study

Published:2021-04 Issue: Volume:159 Page:105724
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Shen Qi,Hu Chao,Miao Jia,Chen Junxia,Peng Yueying,Pan Tingting,He Xiaolin,Yuan Jing,Ni Shaonan,Wang Yongsheng,Luo Zhu

Funder

National Major Science and Technology Projects of China

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference30 articles.

1. Duloxetine treatment adherence across mental health and chronic pain conditions;Able;Clinicoecon Outcomes Res,2014

2. STEPS for cost-effective prescribing of serotonin-norepinephrine reuptake inhibitors (SNRIs) in major depressive disorder: Focus on venlafaxine (Effexor®) versus duloxetine (Cymbalta®);Alipour;Mental Health Clinician,2013

3. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis;Cipriani;Lancet,2018

4. Depression treatment in Germany - using claims data to compare a collaborative mental health care program to the general practitioner program and usual care in terms of guideline adherence and need-oriented access to psychotherapy;Engels;BMC Psychiatry,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of microglia in diabetic neuropathic pain;Frontiers in Cell and Developmental Biology;2024-07-29

2. Review of the Chinese Landscape in Phase 1 Clinical Trials for Noncancer Innovative Drugs Over 2015 to 2020;Clinical Pharmacology in Drug Development;2022-06-16